Canadian Cancer Trials Group / Groupe canadien des essais sur le cancer

NEUROENDOCRINE DISEASE ORIENTED GROUP

CHELSEA HOTEL, TORONTO, ON
ROOM: ROSSETTI
SATURDAY MAY 4, 2019, 1:30 PM – 2:30 PM

CO-CHAIRS : DR. SIMRON SINGH & DR. TIM ASMIS
SENIOR INVESTIGATOR: DR. CHRIS O'CALLAGHAN

CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:
- *To identify and address, through clinical and translational research, the disease burden associated with gastroenteropancreatic neuroendocrine malignancies in Canada.*
- *To identify clinical trial research opportunities for neuroendocrine tumours within the Canadian Cancer Trials Group.*
- *To integrate current knowledge regarding therapeutic and tumour biology of gastroenteropancreatic neuroendocrine malignancies in trial concept development and conduct.*
- *To interpret and apply new clinical trial methodologies in the field of clinical research in gastroenteropancreatic neuroendocrine malignancies.*
- *To provide a learning and mentoring environment supportive to new investigators with an interest in gastroenteropancreatic neuroendocrine malignancies*

Time	Topic	Speaker
1:30 pm	Welcome	Dr. S. Singh Dr. T. Asmis
1:35 pm	COMMNETs – Commonwealth Neuroendocrine Tumour Collaboration	Dr. S. Singh
1:45 pm	RENET: A randomized phase III trial comparing REgorafenib to placebo in patients with advanced, progressive, well-differentiated NEuroendocrine Tumours (NETs)	Dr. S. Singh
2:00 pm	HIGHLANDER (CommNets): High Dose Lanreotide in neuroendocrine tumours	Dr. S. Singh

2:10 pm	Concept: TEMPTATION (AGITG) - Temozolomide and Pembrolizumab Together to Increase Immunogenicity of Advanced Pancreatic Neuroendocrine Tumours	Dr. J. Loree
2:15 pm	Concept: A Phase II study of Immunotherapy In Addition to Radiotherapy in Unresectable/metastatic, progressive Grade 2-3 Neuroendocrine Neoplasms	Dr. S. Myrehag
2:20 pm	Intergroup Task Force Update	Dr. T. Asmis
2:30 pm	Meeting Adjourned	